Christopher Schott
JPMorgan Chase & Co, Analysis Division
Good afternoon, all people. I am Chris Schott at JPMorgan, and it is my pleasure to be internet hosting this fireplace dialogue with Dave Ricks, Chairman and CEO of Eli Lilly. All the time a spotlight of the convention for me. Dave, Comfortable New 12 months. I do know we’ll have some preliminary fast presentation, and we’ll soar into the Q&A from there. So I am going to flip it over to Dave.
David Ricks
Chairman & CEO
Thanks, Chris. Nice. Thanks, everybody, for being right here to hearken to us, and pleased New 12 months to everybody. It is an vital 12 months for Lilly. It is our a hundred and fiftieth 12 months in existence, which I feel makes us probably the most helpful previous firm in America.
Sure. So along with celebrating that, we now have rather a lot to stay up for this 12 months. I feel final 12 months at this convention, we have been coming off a 12 months the place we actually form of had our first full 12 months of weight problems launch with tirzepatide, and there have been numerous unknowns and many uncertainties. And I feel we exit that 12 months and enter ’26 with much more recognized and much more certainty. From a portfolio perspective, after all, tirzepatide is an unimaginable molecule that is altering the lives of hundreds of thousands of individuals all over the world.
However we have been working arduous on follow-on pipeline merchandise. And within the 12 months, I feel we noticed Section III information on the total program for orforglipron, our oral GLP-1, which I am positive we’ll discuss within the Q&A in addition to the primary set of knowledge on
